Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
GeneDx Holdings Corp (NASDAQ: WGS) closed the day trading at $85.74 down -6.41% from the previous closing price of $91.61. In other words, the price has decreased by -$6.41 from its previous closing price. On the day, 0.78 million shares were traded. WGS stock price reached its highest trading level at $91.115 during the session, while it also had its lowest trading level at $84.0421.
Ratios:
For a better understanding of WGS, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.07 and its Current Ratio is at 3.25. In the meantime, Its Debt-to-Equity ratio is 0.45 whereas as Long-Term Debt/Eq ratio is at 0.43.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Guggenheim on May 15, 2025, initiated with a Buy rating and assigned the stock a target price of $88.
On May 09, 2025, Jefferies Upgraded its rating to Buy which previously was Hold but kept the price unchanged to $80.
On August 28, 2024, Wells Fargo started tracking the stock assigning a Equal Weight rating and target price of $34.Wells Fargo initiated its Equal Weight rating on August 28, 2024, with a $34 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jul 01 ’25 when Stueland Katherine sold 9,657 shares for $90.94 per share. The transaction valued at 878,181 led to the insider holds 4,940 shares of the business.
Feeley Kevin sold 1,344 shares of WGS for $122,471 on Jul 01 ’25. The CHIEF FINANCIAL OFFICER now owns 7,425 shares after completing the transaction at $91.12 per share. On Jul 01 ’25, another insider, Kevin Feeley, who serves as the Officer of the company, bought 5,805 shares for $92.32 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, WGS now has a Market Capitalization of 2446436608 and an Enterprise Value of 2589575936. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.41 while its Price-to-Book (P/B) ratio in mrq is 9.50. Its current Enterprise Value per Revenue stands at 7.844 whereas that against EBITDA is 285.101.
Stock Price History:
The Beta on a monthly basis for WGS is 2.08, which has changed by 1.8762159 over the last 52 weeks, in comparison to a change of 0.11708844 over the same period for the S&P500. Over the past 52 weeks, WGS has reached a high of $117.75, while it has fallen to a 52-week low of $25.32. The 50-Day Moving Average of the stock is 14.41%, while the 200-Day Moving Average is calculated to be 12.08%.
Shares Statistics:
Over the past 3-months, WGS traded about 1.18M shares per day on average, while over the past 10 days, WGS traded about 1204330 shares per day. A total of 28.53M shares are outstanding, with a floating share count of 24.88M. Insiders hold about 12.81% of the company’s shares, while institutions hold 101.94% stake in the company. Shares short for WGS as of 1749772800 were 3747783 with a Short Ratio of 3.17, compared to 1747267200 on 3474291. Therefore, it implies a Short% of Shares Outstanding of 3747783 and a Short% of Float of 26.51.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The dynamic stock of GeneDx Holdings Corp (WGS) is currently attracting attention from 4.0 analysts actively involved in rating its market status.The consensus estimate for the next quarter is $0.26, with high estimates of $0.32 and low estimates of $0.21.
Analysts are recommending an EPS of between $1.12 and $0.95 for the fiscal current year, implying an average EPS of $1.07. EPS for the following year is $1.94, with 4.0 analysts recommending between $2.19 and $1.4.
Revenue Estimates
5 analysts predict $85.76M in revenue for the current quarter. It ranges from a high estimate of $86.8M to a low estimate of $84.7M. As of the current estimate, GeneDx Holdings Corp’s year-ago sales were $70.51MFor the next quarter, 5 analysts are estimating revenue of $93.77M. There is a high estimate of $95.2M for the next quarter, whereas the lowest estimate is $92.8M.
A total of 6 analysts have provided revenue estimates for WGS’s current fiscal year. The highest revenue estimate was $373.6M, while the lowest revenue estimate was $367.4M, resulting in an average revenue estimate of $369.53M. In the same quarter a year ago, actual revenue was $305.45MBased on 6 analysts’ estimates, the company’s revenue will be $442.38M in the next fiscal year. The high estimate is $457.2M and the low estimate is $426.97M.
